| Code | CSB-RA021334MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to BI-770371, designed to target signal regulatory protein alpha (SIRPα), a transmembrane glycoprotein expressed on myeloid cells including macrophages, dendritic cells, and granulocytes. SIRPα functions as an immune checkpoint by binding to CD47 on cell surfaces, delivering a "don't eat me" signal that inhibits phagocytosis. This interaction enables cancer cells to evade immune surveillance by preventing macrophage-mediated destruction, making the SIRPα-CD47 axis a critical therapeutic target in oncology. Dysregulation of this pathway has been implicated in various hematologic malignancies and solid tumors, where tumor cells exploit CD47 overexpression to resist innate immune responses.
BI-770371 is a clinical-stage therapeutic antibody that blocks the SIRPα-CD47 interaction, thereby promoting tumor cell phagocytosis and enhancing anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating SIRPα biology, studying macrophage-mediated phagocytosis mechanisms, exploring immune checkpoint modulation, and evaluating combination immunotherapy strategies in preclinical cancer models.
There are currently no reviews for this product.